Dr. Spira is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8613 Route 29
200
Fairfax, VA 22031Phone+1 571-350-8400Fax+1 703-940-8746
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2000 - 2003
- University of Pennsylvania Health SystemResidency, Internal Medicine, 1997 - 2000
- New York University School of MedicineClass of 1997
Certifications & Licensure
- VA State Medical License 2003 - 2026
- MD State Medical License 2000 - 2003
- PA State Medical License 1998 - 2000
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors:Washington DC Area Castle Connolly, 2012
- Top Doctors:Washington-Baltimore Castle Connolly, 2012
- Top MD Consumers Checkbook
Clinical Trials
- Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma Start of enrollment: 2010 Jun 01
- Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
- A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Brief Report: Preventing Infusion-related Reactions With Intravenous Amivantamab: Results From SKIPPirr, a Phase 2 Study.Alexander I Spira, Luis Paz-Ares, Ji-Youn Han, Jin-Yuan Shih, Céline Mascaux
Journal of Thoracic Oncology. 2025-01-24 - Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results F...Benjamin Besse, Koichi Goto, Yongsheng Wang, Se-Hoon Lee, Melina E Marmarelis
Journal of Thoracic Oncology. 2025-01-02 - FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).Alexander Spira, Byoung Chul Cho, Enriqueta Felip, Edward B Garon, Koichi Goto
Lung Cancer. 2024-12-28
Journal Articles
- Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences
- Brigatinib Versus Crizotinib in ALK-Positive Non–Small-Cell Lung CancerD Ross Camidge, Scott N Gettinger, Alexander Spira, The New England Journal of Medicine
- Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR InhibitorAlexander I Spira, Helena A Yu, Clinical Lung Cancer
Abstracts/Posters
- Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...Alexander I. Spira, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...Alexander I. Spira, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Authored Content
- WCLC 2021: Study Improvements Mean Nothing Without PatientsFebruary 2021
- Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR InhibitorAugust 2018
Press Mentions
- Unmet Needs in the Treatment and Management of Non–Small Cell Lung CancerSeptember 26th, 2024
- The SKIPPirr Study: Dr. Spira Shares Insights at IASLC 2024 World Conference on Lung CancerSeptember 12th, 2024
- FDA Approves First-Line Amivantamab-vmjw Plus Lazertinib for NSCLCAugust 21st, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: